Kenjo, Eriya http://orcid.org/0000-0002-3176-2206
Hozumi, Hiroyuki
Makita, Yukimasa http://orcid.org/0000-0002-9566-8286
Iwabuchi, Kumiko A.
Fujimoto, Naoko
Matsumoto, Satoru
Kimura, Maya
Amano, Yuichiro
Ifuku, Masataka
Naoe, Youichi
Inukai, Naoto http://orcid.org/0000-0003-2331-3723
Hotta, Akitsu http://orcid.org/0000-0002-2619-7441
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP20im0210115)
Article History
Received: 18 February 2021
Accepted: 21 October 2021
First Online: 8 December 2021
Competing interests
: The authors declare the following competing interests: E.K., H.H., Y.M., S.M., M.K., Y.A., and N.I. are employees of Takeda Pharmaceutical Company, Ltd. E.K., Y.M., K.A.I., N.F., S.M., M.I., and A.H. have filed patent applications regarding the formulation of LNP and its use for delivering CRISPR. The other authors declare no competing interests.